The Subject Expert Committee (SEC) of the Drug Controller General of India (DCGI) has granted 'in principle' approval to Bharat Biotech for conduct of 'Phase III superiority study and Phase III booster dose study' trials for its intranasal COVID-19 vaccine, reported news agency ANI.
Earlier in mid-December, the company sought permission to conduct clinical trials for its intranasal booster dose.
Bharat Biotech aims to conduct clinical trials on 5,000 subjects (50 per cent vaccinated with Covishield and 50 per cent vaccinated with Covaxin).
Bharat Biotech also manufactures the COVID-19 vaccine Covaxin, which was recently given emergency use authorisation for 12-18 year olds.
FPJ Interview: 'Read History And Form Your Own Perception,' Says Freedom At Midnight Season 2 Actor Anurag Thakur
Bombay HC Slams Kulgaon-Badlapur Municipal Council Over Untreated Sewage In Ulhas River, Warns No OC Without Functional STPs
Bombay HC Refuses To Quash FIR, ECIR Against Ex-Religare Chairperson Rashmi Saluja In ESOP Money Laundering Case
Bombay HC Orders Insurers To Reimburse PPE Costs Charged To Covid Patients During 2020 Hospitalisation
(With inputs from Agencies)
